Surrogate marker | Assessment point | Status of priming | HIV-1 positive | HIV negative | Community controls | ||||
Fe pos (Sgr I) n = 54 | Fe neg (Sgr II) n = 54 | Fe pos (Sgr III) | Fe neg (Sgr IV) | (Sgr V) | |||||
Category of ARI on follow up | Category of ARI on follow up |
|
|
| |||||
PT n = 38 | non-PT n = 16 | PT n = 10 | non-PT n = 44 | n = 30 | n = 50 | n = 40 | |||
Citrulline (µM) | En | Unpr | 1.5 ± 0.8‽‡ | 3.1 ± 1.4‽ | 19.2 ± 3.9# | 16.4 ± 3.9# | 2.7 ± 1.4‽ | 7.2 ± 4.3 | 8.4 ± 3.2 |
Pr | 1.6 ± 0.6 | 3.9 ± 1.8 | 38.6 ± 6.9† | 30.4 ± 4.7† | 2.9 ± 1.6 | 19.3 ± 9.6† | 16.6 ± 8.8† | ||
Fu | Unpr | 18.6 ± 8.2#§* | 11.4 ± 2.7#* | 16.2 ± 7.6# | 21.4 ± 4.7# | NA | NA | NA | |
Pr | 46.6 ± 16.8§†* | 32.8 ± 4.7†* | 34.3 ± 8.2†* | 38.4 ± 9.6†* | NA | NA | NA | ||
Neopterin (µM) | En | Unpr | 0.42 ± 0.21‽‡ | 0.64 ± 0.26‽ | 5.1 ± 2.7# | 3.8 ± 1.7# | 0.49 ± 0.31‽ | 2.1 ± 1.4 | 1.8 ± 1.2 |
Pr | 0.46 ± 0.32 | 0.62 ± 0.21 | 11.4 ± 3.8† | 9.6 ± 1.6† | 0.51 ± 0.38 | 6.1 ± 2.8† | 5.2 ± 1.8† | ||
Fu | Unpr | 8.8 ± 2.6#§* | 4.4 ± 1.8#* | 8.2 ± 3.1# | 5.4 ± 2.6# | NA | NA | NA | |
Pr | 14.1 ± 4.5§†* | 10.2 ± 3.6†* | 12.4 ± 3.8†* | 9.2 ± 3.7†* | NA | NA | NA |